Airway Cellular and Cytokine Profiles in Older Patients with Asthma

老年哮喘患者的气道细胞和细胞因子谱

基本信息

  • 批准号:
    8716660
  • 负责人:
  • 金额:
    $ 21.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-08 至 2015-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The recognition of distinct asthma phenotypes has begun to explain differences in disease severity, persistence and response to treatment in children and younger adults. Emerging data suggest that aging also has an important effect on asthma; older asthmatics have greater morbidity and mortality, possibly reflecting distinct underlying pathophysiology and variable treatment responses. While mechanisms underlying these changes in older asthmatics are not well established, age-related alterations in immune function likely play an important role. To define the effects of age on key features of asthma, airway inflammation and airway hyperresponsiveness (AHR), we first developed a murine model of asthma using Ag sensitization and airway challenge in younger and older mice. Distinct patterns of airway inflammatory responses to Ag challenge were found in older mice characterized by increased IL-6, IL-10, IL-17, TGF-¿ expression and greater numbers of airway neutrophils and Treg cells. To translate our murine findings to humans we next generated preliminary data which suggest enhanced formation of IL-6 and neutrophilia are important to the pathophysiology of asthma in older subjects. We therefore hypothesize that, compared to younger asthmatics, older asthmatics will manifest a distinct inflammatory phenotype indexed by increased generation of IL-6, which, in turn, increases the expression of Th17 cells to induce airway neutrophilia, and also decreases Treg cell function. To test our hypothesis we will collect induced sputum and peripheral blood from 40 older (>60 years) and 40 younger adult (21-40 years) asthmatics (receiving a standardized low dose of inhaled corticosteroids) and 80 age-matched controls. We will then: a) establish the airway inflammatory (cytokine and cellular) phenotypes in the older asthmatic subjects in comparison to younger adult asthma subjects and examine association with asthma control, and b) investigate whether IL-6 contributes to the mechanisms of asthma in the older subjects by enhancing Th17 expression and decreasing Treg function.
描述(通过应用证明):对不同的哮喘表型的识别已经解释了对儿童和年轻人的治疗的差异,这表明衰老也对哮喘具有重要的影响;以及可变的信任反应。在年轻小鼠和年龄较大的小鼠中,使用AG敏化和气道挑战开发了哮喘的鼠模型。表达和更多的嗜中性粒细胞和Treg细胞。由IL-6的产生增加的独特炎症型,可容易地表达Th17细胞诱导气道中性粒细胞,并降低Treg细胞功能,以测试我们的假设。年轻的成年人(21-40岁)吸入皮质类固醇的哮喘患者和80个年龄匹配的对照。哮喘控制和b)研究IL-6是否通过表达d降低Treg功能来促进老年受试者的哮喘机制。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of aging on sputum inflammation and asthma control.
  • DOI:
    10.1016/j.jaci.2016.09.015
  • 发表时间:
    2017-06
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Busse PJ;Birmingham JM;Calatroni A;Manzi J;Goryachokovsky A;Fontela G;Federman AD;Wisnivesky JP
  • 通讯作者:
    Wisnivesky JP
The Effect of Age on T-Regulatory Cell Number and Function in Patients With Asthma.
  • DOI:
    10.4168/aair.2021.13.4.646
  • 发表时间:
    2021-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Birmingham JM;Chesnova B;Wisnivesky JP;Calatroni A;Federman J;Bunyavanich S;Busse PJ
  • 通讯作者:
    Busse PJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAULA J BUSSE其他文献

PAULA J BUSSE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAULA J BUSSE', 18)}}的其他基金

Childhood Asthma in Urban Settings
城市环境中的儿童哮喘
  • 批准号:
    10393042
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
Childhood Asthma in Urban Settings
城市环境中的儿童哮喘
  • 批准号:
    10211261
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
Childhood Asthma in Urban Settings
城市环境中的儿童哮喘
  • 批准号:
    10594976
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
Depression in Older Asthmatics: Understanding Inflammatory and Behavioral Pathways
老年哮喘患者的抑郁症:了解炎症和行为途径
  • 批准号:
    10164846
  • 财政年份:
    2019
  • 资助金额:
    $ 21.19万
  • 项目类别:
Depression in Older Asthmatics: Understanding Inflammatory and Behavioral Pathways
老年哮喘患者的抑郁症:了解炎症和行为途径
  • 批准号:
    10418660
  • 财政年份:
    2019
  • 资助金额:
    $ 21.19万
  • 项目类别:
Airway Cellular and Cytokine Profiles in Older Patients with Asthma
老年哮喘患者的气道细胞和细胞因子谱
  • 批准号:
    8586093
  • 财政年份:
    2013
  • 资助金额:
    $ 21.19万
  • 项目类别:
C1 ESTERASE INHIBITOR AS TREATMENT AND PREVENTION IN HEREDITARY ANGIOEDEMA
C1 酯酶抑制剂治疗和预防遗传性血管性水肿
  • 批准号:
    7953680
  • 财政年份:
    2009
  • 资助金额:
    $ 21.19万
  • 项目类别:
CHANGE TRIAL
变更试用
  • 批准号:
    7718156
  • 财政年份:
    2008
  • 资助金额:
    $ 21.19万
  • 项目类别:
EFFICACY AND SAFETY OF PURIFIED C1 ESTERASE INHIBITOR FOR TREATMENT OF HAE
纯化 C1 酯酶抑制剂治疗 HAE 的功效和安全性
  • 批准号:
    7605311
  • 财政年份:
    2007
  • 资助金额:
    $ 21.19万
  • 项目类别:
Contribution of TNF-alpha to mucus cell production in asthma
TNF-α 对哮喘粘液细胞产生的贡献
  • 批准号:
    7143457
  • 财政年份:
    2006
  • 资助金额:
    $ 21.19万
  • 项目类别:

相似国自然基金

下丘脑室旁核促肾上腺皮质激素释放激素神经元调控奖赏偏好行为的机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
INSM1在静默性促肾上腺皮质激素细胞腺瘤发生发展中的调控机制及潜在靶向治疗研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
促肾上腺皮质激素释放因子通过CRFR1-cAMP-SphK1通路介导肥大细胞脱颗粒参与胰腺癌痛外周敏化
  • 批准号:
    82171232
  • 批准年份:
    2021
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
催产素参与双相障碍发病机制的研究:聚焦于促肾上腺皮质激素释放激素与催产素之间的平衡紊乱
  • 批准号:
    81971268
  • 批准年份:
    2019
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目

相似海外基金

Dose escalation clinical trial of high-dose oral montelukast to inform future RCT in children with acute asthma exacerbations
大剂量口服孟鲁司特的剂量递增临床试验为哮喘急性发作儿童的未来随机对照试验提供信息
  • 批准号:
    10649012
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Dysregulated Immunometabolism and Premature Senescence in Corticosteroid-Refractory Severe Asthma
皮质类固醇难治性严重哮喘的免疫代谢失调和过早衰老
  • 批准号:
    10567868
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and Physiology
评估代谢功能障碍对哮喘病理学和生理学的影响
  • 批准号:
    10688260
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and Physiology
评估代谢功能障碍对哮喘病理学和生理学的影响
  • 批准号:
    10503780
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
BREATHE: An efficacy-implementation trial of a brief shared decision making intervention among Black adults with uncontrolled Asthma in Federally Qualified Health Centers (FQHC).
呼吸:在联邦合格健康中心 (FQHC) 中对哮喘不受控制的黑人成年人进行简短的共同决策干预的功效实施试验。
  • 批准号:
    10402415
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了